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Introduction 
 
Neuropathic pain (NeuP) is defined as pain arising from a lesion or disease of the 
somatosensory nervous system[39; 88]. NeuP is common, affecting approximately 6-8% of 
the general population[14; 86] and currently treatment is inadequate due to both poor drug 
efficacy and tolerability[38]. Many different types of injury can cause neuropathic pain 
including genetic (e.g. SCN9A gain of function variants), metabolic (e.g. diabetic 
polyneuropathy), infective (e.g. HIV associated neuropathy, hepatitis), traumatic and toxic 
(e.g. chemotherapy induced neuropathy) causes. Such injurious events can impact on 
anatomically distinct regions of the somatosensory nervous system ranging from the 
terminals of nociceptive afferents (in small fiber neuropathy) to the thalamus (in post-stroke 
pain). Classification of neuropathic pain using etiology and location remains an important 
aspect of routine clinical practice; however, pain medicine is coming to the realization that 
we need more precision in this classification. The hope is that improved classification will 
lead to better understanding of risk, prognosis and optimal treatment of NeuP.  
 
Patient stratification is the process of identifying subgroups of patients, suffering from a 
disorder (such as NeuP) in order to better target medical intervention[92]. Such sub-groups 
may map to a particular pathogenic mechanism but could also simply be a constellation of 
clinical symptoms and signs or biomarker, which are predictive of treatment response. 
Personalized medicine aims to target intervention to individual patients and is therefore 
even more ambitious in scope[68]. Personalized medicine may be possible in rare cases of 
 2 
 
NeuP (usually associated with specific gene mutations) but for the most part we will discuss 
stratified pain medicine in this review.     
 
Both preclinical and clinical science, have identified an array of pathogenic mechanisms 
underlying NeuP ranging from ectopic activity in primary afferents to defective central pain 
modulation pathway (for a comprehensive review see [18]). It is not a new idea that we 
should be trying to understand pain mechanisms in patients [106; 107] although there are 
challenges in being able to assess specific mechanisms in individual patients. Stratification 
aims to achieve patient subgroupings that have utility in terms of diagnosis, prognosis or 
treatment and this may not relate to a single pathogenic mechanism. Fortunately our 
armamentarium for identifying patient subgroups (and in some cases directly assaying 
pathogenic mechanisms) in patients has greatly improved. In the first section of this 
manuscript we will review the means by which NeuP patients may be stratified and in the 
second section the potential benefits of stratification. Thomas Lewis said, ‘Diagnosis is a 
system of more or less accurate guessing, in which the endpoint achieved is a name. These 
names applied to disease come to assume the importance of specific entities, whereas they 
are for the most part no more than insecure and therefore temporary conceptions’. He was 
likely exaggerating for effect but we hope that patient stratification will not only reduce the 
uncertainty in diagnosis but also help improve prevention, prognostication and treatment. 
 
How can we stratify NeuP patients? 
As in all medicine detailed clinical history and examination remain important in the 
assessment of neuropathic pain. An important aspect on history is the temporal course of 
pain onset and its relationship to the underlying disease process. The examination should be 
comprehensive and relevant to the disease process and history. For example, the presence 
of limb erythema with a diagnosis of erythromelalgia or absent lower limb reflexes as a 
consequence of peripheral neuropathy. Stratification of NeuP patients incorporates a 
multidisciplinary approach. Figure 1 provides a schematic representation of some of the 
techniques that can be used to stratify NeuP patients. A detailed description of the 
techniques will be discussed below.  
 
Sensory phenotype  
 3 
 
In the last decade significant advances in techniques to define somatosensory phenotype in 
the context of NeuP have been developed. These include questionnaires to assess pain 
quality, psychophysical tools to assess sensory perception, and alteration of experimental 
pain through conditioned pain modulation.  
 
Pain quality 
A variety of tools have been developed to both screen and characterize the qualities of 
NeuP. Screening questionnaires, such as the DN4 [12], painDETECT [43] and LANSS[7; 8] are 
used to identify patients with neuropathic pain. The screening questionnaires incorporate 
descriptors of sensory symptoms to generate a score that helps predict whether the pain is 
likely to be neuropathic. Examples include “burning” quality to pain or the presence of 
paresthesias. The DN4 also includes an examination component to test for sensory loss 
and/or allodynia. The above questionnaires can be used to screen for neuropathic pain at a 
primary care level[1]. For example, the DN4 questionnaire has demonstrated excellent 
sensitivity and specificity in screening for NeuP in patients diagnosed with diabetic 
neuropathy (DPN) [81; 85].  The screening questionnaires have been validated to 
discriminate between neuropathic and non-neuropathic pain and translated in to over 90 
languages[1].   The Neuropathic Pain Symptom Inventory (NPSI) [13], is a self-administered 
questionnaire  developed to  characterize the qualities of NeuP.  
 
A major advantage of these questionnaires is that they are self-administered and can be 
used to capture data from large cohorts of patients.  Analysis of large datasets has shown 
that NeuP caused by different etiologies share sensory symptom profiles [5; 42]. The profiles 
may reflect different pathophysiological pathways, independent of etiology, that cause 
NeuP. Hierarchical cluster analysis based on the painDETECT questionnaire of 2100 patients 
diagnosed with painful DPN or postherpetic neuralgia revealed five distinct symptom profile 
subgroups [5]. The different subgroups occurred in both groups of patients. Principal 
component analysis and hierarchical cluster analysis of individual pain dimensions based on 
NPSI descriptors completed by 1225 patients (diagnosed with central post stroke pain, 
painful DPN, painful HIV neuropathy and posttraumatic peripheral pain) identified three 
clusters with distinct symptom profiles [42]. The three clusters represented three different 
subgroups of patients that were seen across the different NeuP syndromes. A smaller study 
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identified six distinct NeuP profiles, based on the NPSI, among patients with a variety of 
NeuP syndromes [80]. Although different clusters were identified in each study, grouping of 
patients based on sensory symptom profiles rather than solely etiology may yield new 
understanding of NeuP neurobiology and improve response to pain therapies. A step 
forward is the integration of questionnaires and sensory testing to better capture 
somatosensory profiles [99].  
 
 
 
Quantitative sensory testing 
Quantitative sensory testing (QST) is a psychophysical tool that assesses evoked sensory 
perception in response to a defined sensory stimulus [69]. The German research network of 
neuropathic pain (DFNS) developed and validated a standardized QST protocol that tests 13 
parameters of sensory function [70]. The sensory modalities include small fiber sensory 
function, such as thermal detection/pain thresholds and pinprick sensitivity, and large fiber 
sensory function, such as mechanical and vibration detection thresholds. The 
standardization of QST data collection has significant advantages. Data collected across 
different centers can be compared against a large control population cohort, controlling for 
age and gender effects, and be combined to significantly increase statistical power [58; 59; 
98]. A limitation of QST is that it requires a significant investment in equipment and 
examinations are lengthy. In a recent study, QST profiles of 1135 patients collected from 
multiple centers with peripheral neuropathic pain revealed three distinct phenotypes [4]. 
The three phenotypes were characterized by sensory loss, thermal hyperalgesia and 
mechanical hyperalgesia. These phenotypes can be found across different etiologies of 
NeuP but vary in frequency [100]. For example, the most common phenotype in diabetic 
polyneuropathy is sensory loss (64%), followed by mechanical hyperalgesia (20%) and 
thermal hyperalgesia (17%). In contrast, post herpetic neuralgia is characterized by the 
mechanical hyperalgesia phenotype (45%), followed by thermal hyperalgesia (35%) and 
sensory loss (20%). Such stratification of neuropathic pain may yield a greater 
understanding of the pathophysiological mechanisms that are shared across somatosensory 
phenotypes or specific to etiology. Somatosensory profiles can also be used to predict 
treatment response (discussed below).  
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Conditioned pain modulation 
Conditioned pain modulation (CPM) refers to the dynamic psychophysical protocols that 
provide insight into an individual’s inhibitory pain modulation processes [46]. If a patient is 
asked to rate the pain intensity of a certain “test stimulus” (such as contact heat applied to 
the volar surface of the forearm), and then given the combination of a noxious 
“conditioning stimulus” (such as immersion of the opposite hand in a hot water bath) and a 
repeated similar “test stimulus”, the perceived pain intensity of the latter “test stimulus” 
will generally be lower than when given alone. CPM efficiency refers to the reduction of 
pain intensity between the two “test stimuli”. Less efficient CPM, was reported for 
chemotherapy-induced neuropathic pain [63] and peripheral neuropathy patients [93] when 
compared to healthy control participants. Thus impaired inhibitory pain modulation 
processes may be present in patients from suffering from NeuP. There is a growing body of 
evidence suggesting that CPM may be an important biomarker of chronic pain and a 
predictor of treatment response. Less efficient pre-operative CPM may predict chronic post-
operative pain [105; 111]. Less efficient CPM was observed in a group of patients with 
painful DPN that reported a larger analgesic response to duloxetine (see below) [112]. While 
CPM holds great promise,  limiting factors include the heterogeneity of protocols,  
significant variability reported in the size and stability of the CPM effect in healthy 
volunteers, and the inability to disentangle different mechanisms in individuals with 
different causes of chronic pain [55]. 
 
Physiological measures: Electrophysiology and functional brain imaging  
Standard neurophysiological techniques, such as nerve conduction studies, investigation of 
trigeminal reflexes (including the blink reflex) and measurement of somatosensory evoked 
potentials, are commonly used to investigate neuropathic pain[25]. These techniques are 
broadly designed to assess the non-nociceptive pathways. They are most helpful in 
confirming a lesion within the peripheral or central somatosensory nervous system.  Despite 
not assessing the pain pathways directly (as C-fibre activity is poorly represented in these 
outputs) emerging evidence does implicate focal demyelination of non-nociceptive Aβ fibers 
in neuropathic pain related to carpal tunnel syndrome [91] and ophthalmic post-herpetic 
neuralgia [89], as these abnormalities are correlated with paroxysmal pain and abnormal 
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sensations. Laser Evoked Potentials (LEPs) is the preferred technique for assessment of 
nociceptive pathway function, due to ease of use and reliability [24]. Pulses of laser 
generated radiant heat are used to selectively excite free nerve endings in the superficial 
skin layers, which activates Aδ and C nociceptors and gives rise to brain evoked potentials 
specifically related to activation of ascending thermal-pain systems. Suppression of LEPs 
suggests a diagnosis of neuropathic pain [89-91]. LEP amplitudes are correlated to the 
severity of constant pain in patients with carpal tunnel syndrome [91] and ophthalmic post-
herpetic neuralgia [89]. Microneurography is a unique neurophysiological technique that 
uses a microelectrode to record nerve activity directly from a peripheral nerve fascicle. It 
has been used to directly study nociceptor afferent activity in a wide range of neuropathic 
pain conditions [31]. Abnormal patterns of firing and distribution of nociceptive afferent 
subclasses have been identified in conditions such as painful DPN[65], painful neuropathy 
[57], small fiber neuropathy [73] and erythromelalgia [66]. Such aberrant activity is thought 
to be a key driver of peripheral neuropathic pain.  The functional brain imaging field has 
adopted stratification of patients to identify pathological mechanisms of pain [87]. The 
descending pain modulatory system (DPMS) is a brainstem–subcortical–cortical network 
that can modulate nociceptive input to the brain. Pre-clinical studies have shown that DPMS 
is important in chronic pain states. Studies that have stratified patients according to NeuP 
contribution have shown that persistent pain may be linked to an imbalance in DPMS 
function, either due to a diminished inhibitory and/or an enhanced facilitatory capacity of 
the DPMS [47; 61; 72].  Patients with hip osteoarthritis pain [47] (before hip replacement 
surgery) that scored higher on painDETECT (i.e. neuropathic pain contribution more likely) 
demonstrated increased facilitatory DPMS activity when compared to patients that scored 
lower on painDTECT (i.e. neuropathic pain contribution less likely). Furthermore functional 
brain imaging has been used to disambiguate the efficacy of different pain treatments using 
an experimental model of central sensitization, which is a contributory pathomechanism  of 
neuropathic pain [102]. After capsaicin induced central sensitization, gabapentin (a 
neuropathic pain medication), when compared to placebo and ibuprofen (non-neuropathic 
pain medication), suppressed resting state connectivity and secondary mechanical 
hyperalgesia evoked neural response in a region of the brainstem DPMS.   
Molecular profiling   
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Genomics is having a growing influence on medical practice in providing a molecular 
pathogenic link to disease as well as clinically relevant outcomes such as treatment 
response. There are many genes that have a role in the pathogenesis of neuropathic pain 
however we will focus on variants in the gene SCN9a which provides one of the best 
examples of modern genomics applied to pain medicine [116]. SCN9a encodes Nav1.7 [6; 
30] which is a voltage gated sodium channel (VGSC) expressed by sensory neurons. A 
number of rare pain disorders which are inherited in a Mendelian fashion are associated 
with mutations in this gene. Bi-allelic inactivating mutations in NaV1.7 result in congenital 
insensitivity to pain (CIP) and anosmia [20]. Heterozygous gain of function mutations in the 
same channel can lead to: inherited erythromelalgia[110] (IEM, characterized by pain and 
erythema of the extremities exacerbated by warmth) or paroxysmal extreme pain disorder 
(PEPD, associated with episodic pain and erythema of the sacrum and mandible triggered by 
mechanical stimulation)[37]. IEM provides an excellent example of how a molecular 
mechanism links to a pathophysiological pain driver. Nav1.7 mutations causing IEM result in 
gain of function of Nav1.7[26] resulting in hyperexcitability of sensory neurons been 
demonstrated both experimentally and by microneurographic recordings from IEM 
patients). There is a broad correlation between the biophysical dysfunction of the ion 
channel and the associated pain syndrome: IEM mutations causing a greater hyperpolarising 
shift in the voltage dependence of activation result in a more severe clinical phenotype [22; 
49].  
 
Small fiber neuropathy (SFN) is a more common condition than IEM presenting with burning 
pain of the extremities associated with small fiber degeneration[84]. A number of rare 
Nav1.7 variants (which are distinct to those causing IEM) have now also been linked to SFN 
and lead to gain of function in this ion channel[36]. Nav1.7 also provides a good example of 
how certain gene variants may not cause Mendelian pain disorders but contribute as risk 
factors for the development and severity of much more common acquired NeuP states. The 
concept being that such variants would not cause symptoms in the naïve state but can 
contribute to NeuP in the context of an environmental stressor such as the development of 
DPN. Studying a carefully phenotyped cohort of patients with DPN there was a higher 
prevalence of rare Nav1.7 variants in those patients with painful (10% of patients) versus 
painless DPN (0 patients) [10]. Two of these novel variants associated with painful DPN were 
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shown to impair inactivation of Nav1.7 resulting in gain of function providing a physiological 
link to the development of pain.  
 
Because not all Nav1.7 variants are likely to be pathogenic careful genetic counselling is 
required and functional analysis of Nav1.7 variants remains critical [103]. Genomics is now 
increasingly been integrated into clinical practice and the ‘100 000 genomes’ project will 
sequence the whole genomes of 75 000 people suffering from rare disorders (including 
familial pain disorders) as part of routine NHS care within the UK[78]. In the future it may 
become routine to sequence the genomes of large populations in order to appropriately 
target health care. The technology for such sequencing is available although there are still 
great challenges in information processing and ascribing pathogenicity to the variants 
found. Techniques are also being developed for high throughput assessment of epigenetic 
changes as well as the downstream effects of gene function including mRNA expression 
(transcriptome), protein expression (proteome) and metabolites (metabolome)[71]. In the 
future these may also be helpful in stratifying NeuP patients. One issue is that unlike 
oncology pathological material from the somatosensory nervous system is not easily 
accessible. However it is becoming possible to generate induced pleuripotent stem cells 
from patients which can provide a scalable source of sensory neurons[17] for molecular, 
physiological[104] and even pharmacological profiling[16]. This really would be an example 
of ‘personalized’ pain medicine however it is likely to have most utility in situations where 
there are strong genetic drivers of neuropathic pain and the workflow would need to be 
streamlined before this could be used in routine clinical practice.For now this is restricted to 
research practice. 
 
Psychological profile and co-morbidities  
NeuP, as with every form of pain, alarms, demands attention and interferes with ongoing 
activities[32].  Consequently, patients with neuropathic pain experience a lower ability to 
accomplish tasks of daily living, a lower quality of life, a lower mood and more sleep 
problems than those without pain[52; 79].  It may be expected that the presence of NeuP 
triggers a cascade of psychosocial processes that may finally maintain or exacerbate 
suffering, distress and disability.  
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To a large extent, these processes are similar to those involved in other forms of pain [23; 
33]. Just as with musculoskeletal pain, anxiety or worrying about the pain and its possible 
consequences may lead to avoidance, and to more pain, distress and disability[97]. 
Nevertheless, the experience of NeuP has some particularities [27]. Avoidance seems to be 
less triggered by a fear that physical activities will increase pain or worsen their condition. 
Patients with neuropathic pain may rather avoid social situations because the feeling of 
clothes against the skin is uncomfortable. The unpredictable nature of paroxysmal pain may 
turn patients generally anxious and uncertain. These specific features in the phenomenology 
of NeuP need to be further explored.  
 
We should go beyond a documentation of the comorbidities that patients experience. We 
need to understand how exactly these problems come about. It will be useful to put the 
assessment and treatment of neuropathic pain within the psychological context of the 
primary disorder. The patient struggling with diabetes and painful DPN has different needs 
from the patient with HIV neuropathy, who both have different needs from the patient with 
post-mastectomy pain syndrome. That way, we will identify what exactly patients are 
worried about, their specific beliefs about illness, pain and treatment, and how these factors 
impact their life. Pain management programs will need to be tailored and adapted to 
account for the specific contexts of NeuP [27]. Unfortunately, there are yet insufficient 
clinical trials allowing us to conclude that psychological treatments for NeuP work[35].  
 
Overall, research on the role of psychological variables in NeuP is a relatively unexplored 
territory. It largely consists of cross-sectional studies. We do not know yet whether and how 
exactly psychological variables causally contribute to the development or maintenance of 
NeuP [52].  Neuropathic pain may well be a condition in which biobehavioural variables 
interact from onset. Anxiety, depression and stress may have a direct impact on disease 
processes and pain. No study has yet explored this hypothesis. Notwithstanding, there is 
strong evidence that anxiety, depression and stress contribute to disease onset and may 
delay wound healing via the immune and neuroendocrine system[56]. Psychological factors 
may also indirectly affect disease. Cognitions and emotions may be obstacles for the 
adoption of a healthy lifestyle, treatment adherence and optimal self-management. Each of 
these pathways may affect underlying disease mechanisms. In diabetes mellitus, patients 
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who are anxious and depressed are less physically active and eat less healthy, exacerbating 
disease processes. Patients who have a low mood, are less adherent to their medication 
regime[45]. Inappropriate beliefs about the illness and treatment, may lead to suboptimal 
treatment and poor self-management [96].  
A more context sensitive approach to the psychology of chronic NeuP is needed that builds 
on what we know from general behavioural science and behavioural pain medicine[34], but 
that translates it to the needs of the specific patient group . 
 
Data integration 
An important question is to what extent is stratification based on different modalities 
correlated?  Taking genotype and sensory profile as an example there is a link between the 
two but this is not an exact match. Patients with IEM with known mutations in Nav1.7 
actually showed surprising diversity in their sensory profile although the vast majority did 
show heat pain hypersensitivity measured by quantitative sensory testing at unaffected skin 
sites[60]. In painful DPN there was a correlation between genotypes and sensory profile but 
only to one measure:  enhanced pressure pain sensitivity was noted in those patients with 
painful DPN with rare Nav1.7 variants compared to those patients without rare Nav1.7 
variants [10]. Taking the approach of starting with the sensory profile of NeuP patients and 
then sequencing candidate genes Binder et al., showed that variants in TRPA1 (an ion 
channel activated by environmental irritants and cold) were associated with paradoxical 
heat sensation [9].  
 
Ultimately the intersection between different modalities may be particularly helpful in 
stratification. We are in the era of ‘big data’ (data generated in large volume, at high 
velocity and in a variety of formats) in which bioinformatics approaches can be used to 
integrate prospective electronic health records, routine investigations and specialized tests 
using biobank material[19; 71]. This requires significant computing power as well as the 
ability to deal with the security and ethical challenges associated with such large amounts of 
personal data. It will be extremely powerful in generating hypotheses that can then be 
tested in focused cohorts providing potent opportunities for future research.  
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Multivariate analysis enables the study of multiple different, possibly correlated, factors as a 
cause of variation within a population and their relationship to pain. To provide an example 
we undertook principal components analysis in patients with painful DPN [76]. This revealed 
that the relationship between pain and different clinical and psychological factors were 
dependent on gender in patients with painful DPN. Multivariate principal components 
analysis, showed that anxiety (as measured with the DAPOS questionnaire), poor glucose 
control (high HbA1c), high BMI and high 7-Day pain diary scores were more prevalent in 
females, while more severe neuropathy (as assessed using the Toronto Clinical Scoring 
System TCSS and IENFD) was more prevalent in males (Figure 2). These findings emphasise 
the importance of one of the simplest forms of stratification: gender, but also the utility in 
studying multiple variables. 
If a stratification measure only has a small effect size or is overly complex and time 
consuming it will not be adopted in clinical practice. For final clinical use therefore 
stratification measures will require extensive optimization and field testing. 
 
Utility of patient stratification: 
 
Diagnosis of neuropathic pain  
An important step in the stratification of patients is to determine the certainty of 
neuropathic pain diagnosis on an individual basis. A revised grading of neuropathic pain has 
been developed by Neuropathic Pain Special Interest Group (NeuPSIG) of the International 
Association for the Study of Pain to facilitate the correct classification of pain as neuropathic 
[40].  The grading is based on the following criteria. Possible neuropathic pain must fulfil 
criteria 1 and 2. Probable neuropathic pain must fulfil criteria 1, 2 and 3. Definite 
neuropathic pain must fulfil all 4 criteria. 
1. Pain with a distinct neuroanatomically plausible distribution. 
2. A history suggestive of a relevant lesion or disease affecting the peripheral or central 
somatosensory system. 
3. Demonstration of distinct neuroanatomically plausible distribution of neuropathic 
pain 
4. Demonstration of the relevant lesion or disease by at least one confirmatory test  
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Neuropathic pain has been shown to be present in a number of previously poorly 
understood conditions, such as recessive dystrophic epidermolysis bullosa and non-freezing 
cold injury [95; 101], in which a neuropathic component may not have been suspected or 
described. Recessive dystrophic epidermolysis bullosa is an inherited dermal condition 
characterized by bullous eruption of the skin and is associated with severe, debilitating pain. 
Application of the new NeupSIG grading system demonstrated that 62% of patients with 
epidermolysis bullosa had a definite diagnosis of neuropathic pain, 24% had a probable 
diagnosis of neuropathic pain, and 13.7% had a possible diagnosis of neuropathic pain [101]. 
Based on this finding, inherited epidermolysis bullosa was shown to cause a small fibre 
neuropathy and patients were started on appropriate neuropathic pain therapies.  Non-
freezing cold injury is an umbrella term used to describe an environmental injury in which 
soldiers that are exposed to cold and wet conditions can develop pain and sensory 
disturbance of the feet and hands. We showed using detailed clinical examination, 
quantitative sensory testing and skin biopsy to determine intra-epidermal nerve fibre 
density (IENFD) that the sensory disturbance is caused by a sensory neuropathy and 
application of the new NeupSIG grading system demonstrated that 95.2% of patients with 
non-freezing cold injury had a definite diagnosis of neuropathic pain (Figure 3) [95]. The 
demonstration of impaired small fiber function in fibromyalgia in particular is interesting. 
Fibromyalgia is a syndrome characterized by widespread pain. Careful phenotyping using 
the NPSI questionnaire, clinical examination, electrophysiology including pain evoked 
potentials, skin biopsy for IENFD, and microneurography  demonstrated that the pain 
experienced in fibromyalgia has a significant neuropathic component caused by dysfunction 
within small fibers [74; 94].  
The revised neuropathic pain grading is a significant improvement on previous approaches 
as it offers a methodical and hierarchical process of diagnosis that can be applied in clinical 
and research settings. It provides a rational basis to prioritize investigations and to 
commence appropriate neuropathic pain treatment.  
 
Understanding pathogenic mechanisms underlying neuropathic pain in patients 
Neuropathic pain is a complex multidimensional clinical entity and the underlying 
pathogenic mechanisms that cause neuropathic pain are not understood. A number of 
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pathogenic mechanisms, based on pre-clinical studies, are postulated to play a role in 
acquired neuropathic pain disorders, such as painful DPN [82]. We believe that a stratified 
approach can help translate findings between the clinical and pre-clinical arenas. As an 
example of the strength of patient stratification we describe how a large multicenter 
observational study incorporated a complex multi-disciplinary approach to explore the 
pathophysiological mechanisms of chronic painful DPN. The first step was the recruitment of 
a large of cohort of patients  that satisfied criteria for definite DPN [83]. A total of 191 
patients with DPN underwent neurological examination, quantitative sensory testing, nerve 
conduction studies, and skin biopsy for IENFD assessment. A set of questionnaires assessed 
the presence of pain, pain intensity, pain distribution, and the psychological and functional 
impact of pain [85]. We then used the NeupSIG grading system of NeuP to separate the 
cohort. Participants were divided into those with painful DPN (NeuP present for at least 
three months) and painless DPN (those without NeuP). We showed that there was a positive 
correlation between greater neuropathy severity, poorer diabetic control, and the presence 
(and severity) of NeuP. This link to neuropathy severity has been independently confirmed 
by Raputova et al. [67]. DPN sensory phenotype was characterized by hyposensitivity to 
applied stimuli that was more marked in those with more severe painful DPN. Therefore, 
the sensory profile of patients with painful DPN was distinct from those patients with 
painless DPN. Once our patient cohort was carefully phenotyped and stratified we 
investigated underlying pathogenic mechanisms. We first explored the contribution of 
genetic variability in NeuP and examined the relationship between variants in Nav1.7 and 
NeuP [11]. No rare variants were found in participants with painless DPN, we identified 
twelve rare Nav1.7 variants in ten (out of 111) study participants with painful DPN. Five of 
these variants had previously been described in the context of other NeuP disorders and 
seven have not previously been linked to NeuP. Those patients with rare variants reported 
more severe pain and greater sensitivity to pressure stimuli on quantitative sensory testing. 
In vitro electrophysiological characterisation for two of the novel variants demonstrated 
gain of function changes as a consequence of markedly impaired channel fast inactivation. 
We were therefore able to link the patient phenotype/genotype to changes within the 
biophysical properties of Nav1.7. We then went on to use functional brain imaging to study 
the neural correlates of chronic NeuP in those with painful DPN using a carefully matched 
group of patients with painless diabetic neuropathy as control[72]. We found that the 
 14 
 
ventrolateral periaqueductal grey which is an important centre for descending pain 
modulation was dysfunctional in those patients with painful DPN. The dysfunction refers to 
altered connectivity between the ventrolateral periaqueductal grey and the descending pain 
modulatory system that may enhance incoming nociceptive input. The degree of 
dysfunction correlated with the intensity of spontaneous pain and the size of cortical 
response to an experimental tonic heat pain. This suggests that a brain based pain 
facilitating mechanism contributes to chronic NeuP in DPN. In aggregate these findings 
illustrate how patient stratification and multi-disciplinary investigation can yield important 
insights into potential pathogenic mechanisms underlying neuropathic pain.  
 
 
 
How can patient stratification aid treatment selection?  
The most obvious example where improved patient stratification is already aiding treatment 
selection is using screening tools and (in some cases) more specialized, investigations to 
recognize pain as neuropathic (as opposed to nociceptive) in order to initiate appropriate 
therapy. Once pain is recognized as neuropathic how can we better target therapies to 
optimize the likelihood of response and minimize side effects? Currently first line agents for 
the treatment of neuropathic pain include: tricyclic antidepressants (eg. amitriptyline), dual 
serotonin and noradrenaline reuptake inhibitors (eg. duloxetine) and the Gabapentinoids 
(eg. pregabalin and gabapentin) [38]. Unfortunately for NeuP conditions these agents have 
failure rates of ≥70% in painful DPN and post-herpetic neuralgia[62]. However, when 
patients do respond this is usually within the first month of treatment, the response is 
lasting and is often accompanied by improved sleep and mood. Currently initial treatment 
selection is usually empirical and is not guided by predicted efficacy but by pragmatic 
decisions on tolerability and often the personal experience of the prescriber (see figure 4). 
Furthermore there is a growing list of second line agents such as opiates, the high dose 
capsaicin patch, lidocaine plasters and Botulinum toxin[38]. In certain cases, antiepileptic 
drugs which block VGSCs may be beneficial. One good example is trigeminal neuralgia which 
responds to Carbamazepine[114]. The hope is that NeuP patient stratification will facilitate 
initial treatment selection to optimize early pain relief and also reduce exposure to drugs 
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which are unlikely to be effective. Such an approach could also enhance clinical trial design 
by stratifying patients into those that are most likely to respond to the study medication.  
 
The pain channelopathies provide an excellent example as to how identifying gene 
mutations, assessing their impact on channel biophysics, pharmacology and structure in 
vitro and in silico then enables us to predict treatment response. IEM is notoriously difficult 
to treat. Mexiletine is a drug related to the local anesthetic lidocaine and is active orally. 
General NeuP treatment guidelines actually advise against the use of mexiletine[38] 
because of poor efficacy and cardiac side effects. However, mexiletine’ss activity in blocking 
mutant Nav1.7, demonstrated in vitro for certain IEM related mutations [21], means that it 
can be helpful in certain cases of IEM.  There are more than 30 mutations which can cause 
IEM and there are a variety of drugs that can block VGSCs (including both local anesthetics 
and anti-epileptic drugs). Is there any means of predicting which mutations (and hence 
which patients) will respond to which drug? 
The fact that the structure of VGSCs has recently been solved at near atomic-resolution [75] 
means that we are now able to visualize where a single mutated residue resides within the 
3-D structure of Nav1.7 and potentially model its impact. Most IEM related Nav1.7 
mutations do not respond to the non-selective VGSC  blocker Carbamazepine; however, 
patients with the V400M were found to clinically respond [41; 109] and the effects of this 
mutation on the channel (hyperpolarizing the voltage dependence of activation) could be 
reversed by Carbamazepine. Structural modelling of Nav1.7 was used to show that two 
other mutations (S241T and I234T) were in close proximity to V400M in 3D space (but note 
not in the linear amino acid sequence)[108; 109]. Both of these mutations led to gain of 
function in Nav1.7 and DRG cell hyper-excitability and in accordance with the structural 
prediction these effects were normalized by Carbamazepine. The acid-test of this hypothesis 
was the subsequent finding that two patients carrying the S241T mutation responded to 
carbamazepine in a double-blind randomized placebo-controlled study[44]. This is a small 
trial in a rare condition but provides proof of concept as to how molecular genetics and 
structural modelling can provide insights relevant to distinct ion channels and clinical 
disorders. Such molecular profiling is now becoming relevant to more common acquired 
neuropathic pain conditions [10]In genetic analysis of a patient suffering from NeuP 
secondary to painful DPN we discovered a mutation (S242T) in Nav1.8. This VGSC is also 
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expressed in sensory neurons and is distinct from but shares homology with Nav1.7. Indeed 
this Nav1.8 mutation is homologous to the Carbamazepine responsive S241T mutation in 
Nav1.7. This variant was found to cause gain of function in Nav1.8 and DRG neuron 
hyperexcitability by our collaborators S Waxman and S Dib-Hajj and as predicted from in 
silico analysis these changes could be normalized by Carbamazepine [50].  A recent trial 
using Lacosamide in small fibre neuropathy provides another example of using molecular 
genetics to stratify NeuP patients. Lacosamide is an anti-epileptic drug which has activity 
against VGSCs including Nav1.7[54]. Lacosamide when used in un-stratified NeuP cohorts 
such as painful diabetic neuropathy has at best limited efficacy[51]. This randomized, 
double-blind, placebo controlled trial recruited patients with small fibre neuropathy and 
specifically those with mutation in Nav1.7. Lacosamide treatment in this group showed 
significant analgesic efficacy in comparison to placebo[28]. The fact that more specific 
blockers of VGSCs are under clinical development [115] will give added impetus to using 
genetics to identify mutations in these ion channels. Pharmacogenomics is not restricted to 
prediction of efficacy but can also be used as a means of predicting adverse outcomes (to 
take a topical example the risk of opiate addiction) and this may be a further application of 
genomics to pain medicine in the future[48].  
 
Sensory profiling is a further stratification measure which may help target treatment[3]. This 
has been incorporated into a number of clinical trials in order to determine in retrospective 
analysis whether stratification according to sensory profile at baseline can predict response 
to the study medication. This has proved the case in a number of studies (for examples see 
[2; 77]) although the findings vary depending on the drug class analyzed [53]. One recent 
study was designed to test ‘a priori’ that patient stratification using sensory profiling could 
help predict treatment efficacy[29].  Patients with painful neuropathy underwent QST at 
baseline which was used to assign patients to an irritable nociceptor or the non-irritable 
nociceptor group. They were then treated with oxcarbazepine versus placebo. The initial 
hypothesis was: that those patients with irritable nociceptor profile would be more 
responsive to oxcarbazepine (a drug which blocks VGSCs and reduces ectopic activity). This 
proved to be the case: there was a significant interaction between phenotype and 
treatment response with a lower NNT for oxcarbazepine in the irritable nociceptor 
(NNT=3.9) versus non-irritable nociceptor (NNT=11) group. CPM is a means of assessing 
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whether some patients may have insufficient endogenous pain modulation as a 
pathophysiological driver of NeuP. The mechanism of action of duloxetine is to restore such 
modulation and indeed those patients with defective CPM were found to be more 
responsive to duloxetine [113].   
 
Data on sensory symptoms is easier to collect than QST however it is not necessarily a 
surrogate[29] and provides different information about the somatosensory nervous system. 
For instance sensory symptoms more are informative about spontaneous pain than evoked 
pains and are not as effective at assessing sensory loss[3]); however, assessment of 
neuropathic pain symptoms (for instance NPSI) can reveal different responses between 
distinct drug classes [15].  
 
In summary both genomics and sensory profiling show some promise in predicting 
treatment efficacy. A stratified approach is not used routinely to inform clinical decision 
making; however, if found to be informative in large scale clinical trials of common acquired 
NeuP states this is likely to facilitate clinical adoption. A schematic showing the continuum 
of improved targeting of pain therapies is shown in Figure 4. 
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Summary and future directions 
We have an impressive array of techniques to identify different patient sub-groups of NeuP 
patients ranging from the relatively simple such as pain symptoms to highly complex 
genomics. In both cases we have seen examples of stratified medicine being employed in 
clinical pain practice whether screening for patients with NeuP or identifying those patients 
with very rare monogenic pain disorders likely to respond to a particular drug. These 
opportunities are likely to grow especially with standardized sensory phenotyping, the use 
of electronic health records and the increased adoption of large scale genome sequencing. 
One challenge will be to understand the relationship between these different stratification 
methods.  For instance, if a patient was found to have a gain of function mutation in a VGSC, 
would this take precedence over a sensory profile which showed deafferentation, which we 
would normally predict would reduce the likelihood of response? Data storage and 
integration within the health service remains a challenge certainly at national scale which 
would provide the greatest traction for stratification. Large scale genomics requires data 
security and also robust procedures for dealing with incidental findings that may not be 
relevant to pain but could be highly relevant to the health of the patient and their family. 
Stratified pain medicine has important implications for drug development and these 
techniques are increasingly being adopted in clinical trials. Although restricting a therapy to 
a sub-group of patients may initially seem an economic disincentive to pharma companies 
the advantage is that this may make the difference between trial success and failure; 
certainly the era of targeted biologics in cancer therapy has set a positive precedent for 
better patient stratification. We hope that Thomas Lewis would be impressed by progress 
over the last 70 years and in particular that we will be taking some of the ‘guessing’ out of 
diagnosis; our aspiration is that the end point will have a more tangible link both to the 
pathophysiological mechanisms driving pain but also be predictive of patient prognosis and 
treatment response. 
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Figure legends 
Figure 1 
Schematic representation of some of the techniques that can be used to stratify neuropathic 
pain patients. Techniques to stratify patients in the context of neuropathic pain have been 
developed over the last decade. These include: detailed clinical assessment, psychophysical 
tools to assess sensory profiles; questionnaires to assess pain quality, pain severity, 
comorbidities and psychological impact; neurophysiological tools that can include nerve 
conduction studies, somatosensory evoked potentials and functional brain imaging; and, 
molecular profiling. Integration of data from diverse sources such as electronic health 
records, routine investigation and specialised investigations from biobank material, followed 
by downstream multivariate analysis provides a framework that will yield improvements in 
diagnosis, prognosis and treatment outcomes.  
 
 
Figure 2 
A: PCA biplot of individuals and variables based on the first 2 principal components in a 
cohort of patients with neuropathic pain secondary to diabetic neuropathy. Dots represent 
individuals projected on the 2-dimensional plot. Individuals are colour coded according to 
gender. Active variables used for constructing the components are projected on the 2-
dimensional plot, with arrows proportional to the variable’s contribution to the principal 
component. Angles between variables (co-sinus) represent their correlation. Arrows pointing 
in opposite directions indicate negatively correlated variables, pointing in the same direction 
indicating positively correlated variables and perpendicular are the uncorrelated variables. 
Centroids of the groups are shown with large dots and ellipses.  
 
B: Correlation of original variables with the principal components. Pearson's R correlation 
coefficient is shown only when significant (p value < 0.05) for active continuous variables. 
Principal component’s association with the supplementary categorical variables “Male” and 
“Female” was calculated using one-way ANOVA. The first component (PC1) was strongly and 
significantly associated with anxiety, body mass index (BMI), high self-reported scores, 
younger age, and high HbA1c (glycosylated haemoglobin) and the second component (PC2) 
 21 
 
was associated with more severe neuropathy and low intra-epidermal nerve fibre density 
(IENFD) (Figure B). Principal component 1, was also significantly associated with females. 
The rows highlighted in green are for positively correlated variables. The rows highlighted in 
orange are for negatively correlated variables.  
 
C-E: Boxplots showing the median and the interquartile range for TCSS (Toronto Clinical 
Scoring System a measure of neuropathy severity) total score, DAPOS anxiety score and 7-
Day pain diary mean score for males and females. The two-sided Mann-Whitney Wilcoxon 
rank sum test was used to compare groups. Males had significantly higher TCSS scores 
(Figure C) while women reported significantly higher anxiety (Figure D) and scores in the 7-
Day pain diary (Figure E) (p value < 0.05 *, p value < 0.01 **). 
 
The analysis completed in this figure adopted the same techniques as applied in Sieberg et 
al. [76]. The current data was restricted to only those patients with neuropathic pain.   
 
Figure 3 
This provides an example of how detailed phenotyping and application of the NeupSIG 
grading system was applied to non-freezing cold injury. Non-freezing cold injury arises 
following exposure to a cold wet environment, most commonly in army service personnel. 
This condition is associated with disabling chronic pain but the basis of this pain remained 
mysterious. All study participants gave a history of exposure to a cold wet environment with 
acute onset of sensory symptoms (pain, numbness and paresthesia) that then persisted for 
at least 3 months. Pain was present symmetrically in the hands and feet (a body map is 
shown). Possible neuropathic pain was fulfilled in 100% of cases. Bed-side clinical sensory 
examination and quantitative sensory examination revealed sensory loss in the hands and 
feet and all subjects met criteria for probable neuropathic pain. Skin biopsy revealed 
reduced intra-epidermal nerve fibers confirming a lesion at structural level and 95% of study 
participants met criteria for definite neuropathic pain. Data used in figure derived from Vale 
et al., [92].  
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Figure 4 
A schematic showing the continuum of improved targeting of pain therapies. 
Current first line agents for the treatment of neuropathic pain include: tricyclic 
antidepressants (eg. amitriptyline), dual serotonin and noradrenaline reuptake inhibitors 
(eg. duloxetine) and the Gabapentinoids (eg. pregabalin and gabapentin). Initial treatment 
selection is usually empirical and is not guided by predicted efficacy in individual patients.  
Sensory profiling is a stratification measure which may help target treatment. Patients with 
an “irritable nociceptor” phenotype, a profile with preserved small-fiber function together 
with hyperalgesia, obtain a greater analgesic response to oxcarbazepine than to placebo. 
The most specific and personalized treatments are based on the identification of genetic 
variants that are functionally responsive to specific drugs.   Structural modelling of the ion 
channel (illustrated) can aid in predicting such a treatment response. The use of 
carbamazepine or mexiletine, which can normalize the gain of function effects in certain 
Nav1.7 mutations associated with inherited erythromelagia, is the prototypical example of 
such a personalized approach.  
SNRI- Serotonin and Noradrenaline Reuptake Inhibitors 
(Figure of sodium channel adapted with permission from Blesneac I, Themistocleous AC, 
Fratter C, Conrad LJ, Ramirez JD, Cox JJ, Tesfaye S, Shillo PR, Rice ASC, Tucker SJ, Bennett 
DLH. Rare NaV1.7 variants associated with painful diabetic peripheral neuropathy. Pain. 
2018 Mar; 159(3):469-480. doi: 10.1097/j.pain.0000000000001116, 
https://journals.lww.com/pain/fulltext/2018/03000/Rare_NaV1_7_variants_associated_ 
with_painful.10.aspx)  
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